Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Surgery Seems Superior to Angioplasty in Young Patients

Long-term follow-up of patients under 50 with multivessel coronary artery disease suggests surgery outcomes are significantly better than angioplasty outcomes. This study, presented at the Society of Thoracic Surgeons’ (STS) Annual Meeting, concludes that surgery should continue as plan A when it comes to young patients with three-vessel disease.

La cirugía parece superior a la angioplastia en pacientes jóvenesSurgeons complain that many patients never actually hear their opinion before revascularization. We must acknowledge that to be true, since we often say something like I can revascularize all of your arteries without cracking your chest open, and you can go home much quicker. Our information usually does not extend over time.

 

Both US and European guidelines advocate for a full heart team approach, something that is not frequent in daily practice (particularly when we can carry out “ad hoc” angioplasties). However, these guidelines are based in works dealing with patients around 70 years old, whose outcomes may be different from those for people under 50.


Read also: Is Emergency Cardiac Surgery Necessary in TAVR?


This study included 200 patients with a mean age of 45 years old who underwent myocardial revascularization surgery or angioplasty between 2004 and 2016.

 

At 5 years, angioplasty patients had increased risk of infarction (9% vs. 1%; p = 0.02), repeat revascularization (31% vs. 7%; p < 0.01), and hospital readmission (45% vs. 10%; p < 0.001).

 

The combined endpoint (all-cause death, stroke, infarction, or repeat revascularization) was higher for those treated with angioplasty (34% vs. 12%; p < 0.01).


Read also: Angioplasty vs. Surgery in Long-Term Critical Ischemia.


At 12 years, surgery still maintained an advantage in terms of repeat revascularization and readmission (p < 0.001 for both).

 

When patients were stratified by how many vessels were affected, event rates were similar in those with single- and two-vessel disease at 5 years.

 

In patients with three-vessel disease, angioplasty was associated with greater rates of repeat revascularization (36.4% vs. 7.6%; p < 0.01) and combined events (36.4% vs. 12.7%; p = 0.02) when compared with surgery. At 12 years, surgery also had an advantage in terms of infarction.


Read also: Quality of Life Between Surgery and Angioplasty for the Treatment of Left Main Disease.


Patients who underwent surgery were more likely to be diabetic, had lower ejection fraction, and were more likely to have peripheral vascular disease.

 

As usual, in works with such a long follow-up period, the technology used at the time the procedures were carried out is not the same technology we use in current clinical practice. Almost a fourth of all patients who underwent angioplasty received bare-metal stents (BMS).

 

Original title: Coronary Artery Bypass Surgery Compared to Percutaneous Coronary Intervention in Patients Younger than 50 Years of Age: Long-Term Outcomes.

Reference: Awad WI et al. Presented at the Society of Thoracic Surgeons Annual Meeting. Fort Lauderdale, FL.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...